These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 26866293)

  • 1. Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials.
    Vashisht P; Sayles H; Cannella AC; Mikuls TR; Michaud K
    Arthritis Care Res (Hoboken); 2016 Oct; 68(10):1478-88. PubMed ID: 26866293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials.
    Zink A; Strangfeld A; Schneider M; Herzer P; Hierse F; Stoyanova-Scholz M; Wassenberg S; Kapelle A; Listing J
    Arthritis Rheum; 2006 Nov; 54(11):3399-407. PubMed ID: 17075823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice.
    Aaltonen KJ; Ylikylä S; Tuulikki Joensuu J; Isomäki P; Pirilä L; Kauppi M; Rannio T; Eklund K; Blom M; Nordström D
    Rheumatology (Oxford); 2017 May; 56(5):725-735. PubMed ID: 28064209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Challenge of Treating Early-Stage Rheumatoid Arthritis: The Contribution of Mixed Treatment Comparison to Choosing Appropriate Biologic Agents.
    Migliore A; Bizzi E; Petrella L; Bruzzese V; Cassol M; Integlia D
    BioDrugs; 2016 Apr; 30(2):105-15. PubMed ID: 26905069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Biologic Therapy in Racial Minorities With Rheumatoid Arthritis From 2 US Health Care Systems.
    Kerr GS; Swearingen C; Mikuls TR; Yazici Y
    J Clin Rheumatol; 2017 Jan; 23(1):12-18. PubMed ID: 28002151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis.
    Sokka T; Pincus T
    Arthritis Rheum; 2003 Feb; 48(2):313-8. PubMed ID: 12571838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incomplete reporting of recruitment information in clinical trials of biologic agents for the treatment of rheumatoid arthritis: a review.
    Simsek I; Yazici Y
    Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1611-6. PubMed ID: 22556105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
    Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
    J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or american college of rheumatology criteria for remission.
    Sokka T; Pincus T
    J Rheumatol; 2003 Jun; 30(6):1138-46. PubMed ID: 12784382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
    Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
    Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rheumatoid arthritis patients fulfilling Korean National Health Insurance reimbursement guidelines for anti-tumor necrosis factor-α treatment and comparison to other guidelines.
    Hur JW; Choe JY; Kim DW; Kim HA; Kim SH; Kim WU; Kim YS; Lee HS; Lee SH; Park SH; Park W; Park YB; Suh CH; Shim SC; Song YW; Yoon BY; Yu DY; Yoo DH
    Rheumatol Int; 2015 Nov; 35(11):1817-23. PubMed ID: 26342296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons.
    Graudal N; Jürgens G
    Arthritis Rheum; 2010 Oct; 62(10):2852-63. PubMed ID: 20560138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pragmaticism of Randomized Controlled Trials of Biologic Treatment With Methotrexate in Rheumatoid Arthritis: A Systematic Review.
    Choi MY; Barnabe C; Barber CE; Bykerk V; Pope JE; Hazlewood GS
    Arthritis Care Res (Hoboken); 2019 May; 71(5):620-628. PubMed ID: 29908014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of biological agents in the older rheumatoid arthritis patients compared to Young: A systematic review and meta-analysis.
    Dalal DS; Duran J; Brar T; Alqadi R; Halladay C; Lakhani A; Rudolph JL
    Semin Arthritis Rheum; 2019 Apr; 48(5):799-807. PubMed ID: 30185379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis.
    Bonafede M; Johnson BH; Princic N; Shah N; Harrison DJ
    J Med Econ; 2015 May; 18(5):376-89. PubMed ID: 25530318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Rheumatoid Arthritis Treatments for 'Old' Patients: Results of a Systematic Review.
    Caporali R; Fakhouri WKH; Nicolay C; Longley HJ; Losi S; Rogai V
    Adv Ther; 2020 Sep; 37(9):3676-3691. PubMed ID: 32705531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries.
    Curtis JR; Jain A; Askling J; Bridges SL; Carmona L; Dixon W; Finckh A; Hyrich K; Greenberg JD; Kremer J; Listing J; Michaud K; Mikuls T; Shadick N; Solomon DH; Weinblatt ME; Wolfe F; Zink A
    Semin Arthritis Rheum; 2010 Aug; 40(1):2-14.e1. PubMed ID: 20674669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?
    Levesque MC
    BioDrugs; 2012 Apr; 26(2):65-70. PubMed ID: 22385403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are clinical trials in rheumatoid arthritis generalizable to routine practice? A re-evaluation of trial entry criteria.
    Kingsley GH; Khoshaba B; Smith CM; Choy EH; Scott DL
    Rheumatology (Oxford); 2005 May; 44(5):629-32. PubMed ID: 15705630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.